Showing 1 - 10 of 69,648
The Covid-19 pandemic tragically emphasized severe failures of health systems. In particular, the saturation of hospital infrastructures and the lack of medical devices is crucial for respiratory ventilators. The medical and pharmaceutical sectors had to find urgently new ways to innovate...
Persistent link: https://www.econbiz.de/10014308369
In October 2002, a substitution reform was introduced in the Swedish pharmaceuticals market. In this paper, the effects of increased price competition due to the reform on the entry of new pharmaceutical products were studied. The results show that the reform did affect the entry behavior of...
Persistent link: https://www.econbiz.de/10010277132
The manufacturing sector of the pharmaceutical industry has faced criticism for disparities in access to pharmaceuticals, especially within the context of past incidents and the COVID-19 pandemic. Balancing profitability with the public responsibility to produce affordable, safe and effective...
Persistent link: https://www.econbiz.de/10014565163
In October 2002, a substitution reform was introduced in the Swedish pharmaceuticals market. In this paper, the effects of increased price competition due to the reform on the entry of new pharmaceutical products were studied. The results show that the reform did affect the entry behavior of...
Persistent link: https://www.econbiz.de/10009240823
This paper examines competition between generic and brand-name drugs in the regulated Spanish pharmaceutical market. A nested logit demand model is specified for the three most consumed therapeutic subgroups in Spain: statins (anticholesterol), selective serotonin reuptake inhibitors...
Persistent link: https://www.econbiz.de/10013124302
This paper examines statins competition in the Spanish pharmaceutical market, where prices are highly regulated, and simulates a situation in which there is unrestricted price competition. A nested logit demand model is estimated with a panel of monthly data for pharmaceuticals prescribed from...
Persistent link: https://www.econbiz.de/10013124304
This paper empirically examines the influence of the determinants of R&D expenditure, such as firm's lagged profitability, R&D intensity, and cash flow on R&D expenditure of the pharmaceutical companies. All of them have an important roles in determining the steps of the corporate strategy to...
Persistent link: https://www.econbiz.de/10013125996
This paper examines the idea that the USA has outshined Europe in the race for new medicines as a result of a flight of business R&D expenditure to the USA. It adopts a methodology that accounts for R&D price inflation, considers the role of both ‘performed' R&D and ‘extra-mural' R&D, and...
Persistent link: https://www.econbiz.de/10013155663
Lanjouw and Schankerman (2004) proposed that patent quality is a key driver of R&D productivity but did not find supportive evidence for pharmaceuticals. This study revisits this hypothesis using OECD data for the period 1980-2000. It extends the literature in three ways: it develops new R&D...
Persistent link: https://www.econbiz.de/10013155664
Current business models have struggled to support early-stage drug development. In this paper, we study an alternative financing model, the mega-fund structure, to fund drug discovery. We extend the framework proposed in previous studies to account for correlation between phase transitions in...
Persistent link: https://www.econbiz.de/10012822897